Informuta Inc.

Based in the US, Informuta specializes in providing advanced solutions for forecasting treatment-emergent antimicrobial resistance, equipping healthcare professionals with vital tools to enhance patient care and combat rising resistance rates. Informuta, founded in 2023 by Co-founder and CEO Kalen Hall and CTO and co-founder Leo Williams, is located in San Diego, US. The company focuses on developing technology that predicts antimicrobial resistance patterns. It has completed one deal as of March 3, 2026.

The firm does not have publicly available information regarding its founder or CEO. Informuta specializes in a unique platform designed to forecast treatment-emergent antimicrobial resistance, providing clinicians with the crucial ability to select therapies that are less likely to fail patients, particularly those at high risk. The core product utilizes advanced AI-driven analysis to map whole-genome mutational signatures, allowing for the prediction of future resistance developments based on extensive longitudinal data sets. This service is aimed at healthcare professionals, including clinical microbiology labs, infectious disease pharmacists, and antimicrobial stewardship programs, and seeks to address the rising rates of antimicrobial resistance projected to lead to millions of deaths by 2050.

While specific geographical markets are not disclosed, the platform is designed for use in various healthcare settings, particularly in regions experiencing a significant increase in resistance rates, as highlighted by the World Health Organization (WHO) reports. The technology has undergone rigorous peer-reviewed validation, demonstrating its efficacy and accuracy in real-world clinical applications, with ongoing collaborations with leading healthcare institutions to enhance its deployment. Informuta's revenue model is structured around partnerships with healthcare providers and institutions, where the core service is offered as a subscription-based model or through direct contractual agreements. Clients, including clinical microbiology labs and healthcare systems, may engage with Informuta to integrate its forecasting platform into their existing workflows, enhancing their capabilities in managing antimicrobial resistance.

The company’s primary offerings, which include its predictive resistance forecasting technology, are tailored to meet the needs of healthcare practitioners striving for better patient outcomes. While specific pricing structures for these services are not outlined, financial arrangements are anticipated to reflect the value of advanced data analytics and peer-reviewed insights that inform treatment decisions. The anticipated product launch in late 2026 signals a strategic move to solidify client partnerships and expand market presence within the healthcare sector focused on antimicrobial stewardship. Informuta plans to launch its predictive resistance forecasting technology in late 2026, aiming to enhance its market presence and strengthen client partnerships.

The company is also targeting expansion into new healthcare markets that experience rising antimicrobial resistance rates. In March 2026, Informuta raised an undisclosed amount of Seed funding co-led by Community Development Venture Capital Alliance and New Orleans BioFund. The company will use this funding to support its growth and expansion initiatives.